Margaret Kempen - Core Laboratories Director
| CLB Stock | USD 21.28 0.16 0.76% |
Director
Ms. Margaret Ann van Kempen has served as Independent Member of the Board of Supervisory Directors of Core Laboratories N.V. since May 16, 2012. She is Member of the Compensation Committee and the Nominating, Governance and Corporationrationrate Responsibility Committee at the Company. Ms. van Kempen was the owner and managing partner of Van Kempen Public Relations Public Affairs since 1997. She has experience in strategic corporate communications and investor relations, with a focus on reputation and risk management. She has provided litigation PR and communications advice on a wide variety of issues in high profile cases in and outside The Netherlands. Her clients cover a range of sectors including telecommunications, energy, information technology, professional services and fashion. From 1988 to 1995 she was Director European Affairs of Financial Times Television. Before that she worked in government and semigovernment organizations including the Ministry of Economic Affairs. since 2012.
| Age | 67 |
| Tenure | 12 years |
| Address | 6316 Windfern Road, Houston, TX, United States, 77040 |
| Phone | 713 328 2673 |
| Web | https://www.corelab.com |
Core Laboratories Management Efficiency
The company has Return on Asset of 0.0589 % which means that on every $100 spent on assets, it made $0.0589 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1116 %, implying that it generated $0.1116 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.15. The current year's Return On Capital Employed is expected to grow to 0.21. At present, Core Laboratories' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 26 M, whereas Total Assets are forecasted to decline to about 550.2 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Roderick Larson | Newpark Resources | 53 | |
| Eric Mattson | NOV Inc | 68 | |
| Deanna Goodwin | Oceaneering International | 55 | |
| Lawrence Dickerson | Oil States International | 68 | |
| Jay Thornton | North American Construction | 62 | |
| Amy Kreisler | RPC Inc | 51 | |
| William Kleef | Oil States International | 68 | |
| William Thomas | NOV Inc | 68 | |
| Brian Truelove | Bristow Group | 62 | |
| Melody Meyer | NOV Inc | 63 | |
| Patrick Gunning | RPC Inc | 61 | |
| Lorin Brass | Bristow Group | 66 | |
| Alan Boyd | Cactus Inc | N/A | |
| John Minge | Newpark Resources | 58 | |
| Paul Coppinger | Now Inc | 59 | |
| Deborah Adams | MRC Global | 60 | |
| Jon Reinhardsen | Oceaneering International | 65 | |
| James Hackett | NOV Inc | 67 | |
| Harry Cynkus | RPC Inc | 70 | |
| Maryanne Miller | Bristow Group | 61 | |
| Maryse SaintLaurent | North American Construction | 60 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0589 |
Core Laboratories Leadership Team
Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwendolyn MBA, Senior Relations | ||
| J Dumas, Vice President Business Development | ||
| Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board | ||
| Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | ||
| Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board | ||
| Kevin Daniels, Vice President, Chief Accounting Officer | ||
| Jacobus Schouten, Managing Director | ||
| Christopher Hill, Chief Financial Officer, Senior Vice President | ||
| Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board | ||
| Sow Teo, Treasurer VP | ||
| Gregory Barnett, Non-Executive Independent Member of the Supervisory Board | ||
| Margaret Kempen, Independent Member of the Board of Supervisory Directors | ||
| Mark Tattoli, Senior Vice President General Counsel, Secretary | ||
| Mark Elvig, Senior Vice President, Secretary, and General Counsel | ||
| Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board | ||
| Michael Straughen, Non-Executive Independent Member of the Supervisory Board | ||
| Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations | ||
| Leslie Linklater, Organization, People |
Core Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0589 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.13 B | ||||
| Shares Outstanding | 46.95 M | ||||
| Shares Owned By Insiders | 0.85 % | ||||
| Shares Owned By Institutions | 99.15 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 101.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Core Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Core Laboratories' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Core Laboratories Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Core Laboratories Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Oil & Gas Equipment & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.316 | Dividend Share 0.04 | Earnings Share 0.54 | Revenue Per Share 11.158 | Quarterly Revenue Growth 0.072 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.